Elevance Health Reports Third Quarter 2024 Results

Go back to Elevance Health Reports Third Quarter 2024 Results

Elevance (ELV) PT Lowered to $515 at Leerink Partners

October 21, 2024 5:57 AM EDT

Leerink Partners analyst Whit Mayo lowered the price target on Elevance (NYSE: ELV) to $515.00 (from $620.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: Reiterate Outperform Rating. 3Q results brought forth a material acceleration of pressures within Medicaid as a result of... More

Elevance (ELV) PT Lowered to $478 at RBC Capital

October 18, 2024 7:04 AM EDT

RBC Capital analyst Ben Hendrix lowered the price target on Elevance (NYSE: ELV) to $478.00 (from $585.00) while maintaining a Outperform rating.

The analyst comments "ELV shares traded off today as management lowered its 2024 EPS guidance and guided to mid-single-digit EPS growth in 2025, down from... More

Elevance Health Inc. (ELV) Misses Q3 EPS by $1.29, Beats on Revenue

October 17, 2024 6:01 AM EDT

Elevance Health Inc. (NYSE: ELV) reported Q3 EPS of $8.37, $1.29 worse than the analyst estimate of $9.66. Revenue for the quarter came in at $44.7 billion versus the consensus estimate of $43.46 billion.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

... More